Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 5166 | 2012 |
Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 5005 | 2011 |
Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3328 | 2014 |
Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3190 | 2013 |
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo … K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ... The lancet oncology 13 (10), 983-992, 2012 | 1677 | 2012 |
Apalutamide treatment and metastasis-free survival in prostate cancer MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... New England Journal of Medicine 378 (15), 1408-1418, 2018 | 1317 | 2018 |
Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1251 | 2015 |
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1036 | 2016 |
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial ME Gore, C Szczylik, C Porta, S Bracarda, GA Bjarnason, S Oudard, ... The lancet oncology 10 (8), 757-763, 2009 | 709 | 2009 |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 641 | 2017 |
Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial—FIRSTANA S Oudard, K Fizazi, L Sengeløv, G Daugaard, F Saad, S Hansen, ... Journal of Clinical Oncology 35 (28), 3189-3197, 2017 | 372 | 2017 |
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ... European urology 66 (5), 815-825, 2014 | 344 | 2014 |
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant … CJ Logothetis, E Basch, A Molina, K Fizazi, SA North, KN Chi, RJ Jones, ... The lancet oncology 13 (12), 1210-1217, 2012 | 324 | 2012 |
Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ... LIPPINCOTT WILLIAMS & WILKINS, 2016 | 232 | 2016 |
Apalutamide and overall survival in prostate cancer MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... European urology 79 (1), 150-158, 2021 | 225 | 2021 |
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study … HJ Schmoll, D Cunningham, A Sobrero, CS Karapetis, P Rougier, ... Journal of clinical oncology 30 (29), 3588-3595, 2012 | 220 | 2012 |
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of … E Basch, K Autio, CJ Ryan, P Mulders, N Shore, T Kheoh, K Fizazi, ... The lancet oncology 14 (12), 1193-1199, 2013 | 204 | 2013 |
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma ME Gore, C Szczylik, C Porta, S Bracarda, GA Bjarnason, S Oudard, ... British journal of cancer 113 (1), 12-19, 2015 | 200 | 2015 |
Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. M Gore, P Mainwaring, R A'hern, V MacFarlane, M Slevin, P Harper, ... Journal of clinical oncology 16 (7), 2426-2434, 1998 | 168 | 1998 |
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer A Sobrero, S Ackland, S Clarke, R Perez-Carrión, S Chiara, J Gapski, ... Oncology 77 (2), 113-119, 2008 | 167 | 2008 |